Mind Medicine (MindMed) Management
Management criteria checks 2/4
Mind Medicine (MindMed)'s CEO is Rob Barrow, appointed in Jun 2021, has a tenure of 3.92 years. total yearly compensation is $2.67M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $1.83M. The average tenure of the management team and the board of directors is 1.5 years and 3.6 years respectively.
Key information
Rob Barrow
Chief executive officer
US$2.7m
Total compensation
CEO salary percentage | 23.36% |
CEO tenure | 3.9yrs |
CEO ownership | 0.4% |
Management average tenure | 1.5yrs |
Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Apr 21MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Jan 29Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Nov 04Psychedelic Stocks: Focus On Their Cash
Aug 15MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Jun 05Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2025 | n/a | n/a | -US$78m |
Dec 31 2024 | US$3m | US$624k | -US$109m |
Sep 30 2024 | n/a | n/a | -US$98m |
Jun 30 2024 | n/a | n/a | -US$102m |
Mar 31 2024 | n/a | n/a | -US$125m |
Dec 31 2023 | US$2m | US$599k | -US$96m |
Sep 30 2023 | n/a | n/a | -US$77m |
Jun 30 2023 | n/a | n/a | -US$75m |
Mar 31 2023 | n/a | n/a | -US$63m |
Dec 31 2022 | US$5m | US$672k | -US$57m |
Sep 30 2022 | n/a | n/a | -US$69m |
Jun 30 2022 | n/a | n/a | -US$69m |
Mar 31 2022 | n/a | n/a | -US$98m |
Dec 31 2021 | US$12m | US$350k | -US$93m |
Compensation vs Market: Rob's total compensation ($USD2.67M) is about average for companies of similar size in the US market ($USD2.67M).
Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.
CEO
Rob Barrow (35 yo)
Mr. Robert Barrow, also known as Rob, serves as Chief Executive Officer at Mind Medicine (MindMed) Inc since June 9, 2021 and serves a its Director since December 13, 2021. He served as Chief Development O...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 3.9yrs | US$2.67m | 0.37% $ 1.8m | |
Chief Legal Officer & Corporate Secretary | 2.1yrs | US$1.16m | 0.072% $ 357.2k | |
Chief Medical Officer | 4.3yrs | US$1.33m | 0.33% $ 1.7m | |
Co-Founder & Clinical Advisor | no data | US$501.19k | no data | |
Co-Founder | no data | no data | no data | |
Senior Vice President of Pharmaceutical Development & Operations | less than a year | no data | no data | |
VP & Chief Accounting Officer | 2.5yrs | no data | 0.065% $ 326.3k | |
Chief Corporate Affairs Officer | less than a year | no data | no data | |
Chief Regulatory & Quality Assurance Officer | less than a year | no data | no data | |
Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: MNMD's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 3.4yrs | US$2.67m | 0.37% $ 1.8m | |
Independent Chairperson | 3.7yrs | US$195.03k | 0.022% $ 109.2k | |
Independent Director | 1.9yrs | US$153.67k | 0.014% $ 70.1k | |
Independent Director | 2.8yrs | US$149.81k | 0.023% $ 116.4k | |
Chair of Scientific Advisory Board | 4.2yrs | no data | no data | |
Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
Independent Vice Chairman | 3.7yrs | US$185.03k | 0.0052% $ 25.7k | |
Independent Director | 2.8yrs | US$149.81k | 0.023% $ 116.4k | |
Member of Scientific Advisory Board | less than a year | no data | no data | |
Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
Member of Scientific Advisory Board | 3.5yrs | no data | no data |
Experienced Board: MNMD's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/19 10:17 |
End of Day Share Price | 2025/05/19 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mind Medicine (MindMed) Inc. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joel Beatty | Baird |
Tania Armstrong-Whitworth | Canaccord Genuity |
Sumant Satchidanand Kulkarni | Canaccord Genuity |